Paper
0
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Authors
Raphael Landovitz,Deborah Donnell
Meredith Edwards,Brett Hanscom,Leslie Cottle,Lara Coelho,Robinson Cabello,Suwat Chariyalertsak,Eileen Dunne,Ian Frank,Jorge Gallardo-Cartagena,Aditya Gaur,Pedro Gonzáles,Tran Ha,Juan Hinojosa,Esper Kallás,Colleen Kelley,Marcelo Losso,José Madruga,Keren Middelkoop,Nittaya Phanuphak,Breno Santos,Omar Sued,Javier Valencia,Edgar Overton,Shobha Swaminathan,Carlos Rı́o,Roy Gulick,Paul Richardson,Philip Sullivan,Estelle Piwowar‐Manning,Mark Marzinke,Craig Hendrix,Maoji Li,Zhe Wang,Jeanne Marrazzo,Eric Daar,Aida Asmelash,Todd Brown,Peter Anderson,Susan Eshleman,Marcus Bryan,Cheryl Blanchette,Jonathan Lucas,Christina Psaros,Steven Safren,Jeremy Sugarman,Hyman Scott,Joseph Eron,Sheldon Fields,Nirupama Sista,Kailazarid Gomez-Feliciano,Andrea Jennings,Ryan Kofron,Timothy Holtz,Katherine Shin,James Rooney,Kimberly Smith,William Spreen,David Margolis,Alex Rinehart,Adeola Adeyeye,Myron Cohen,Marybeth McCauley
+62 authors
,Beatriz GrinsztejnPublished
Aug 11, 2021
Show more
Save
Tip0
TipSave
Abstract
Safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preventing HIV infection.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.